Quarterly report pursuant to Section 13 or 15(d)

Condensed Statement Of Operations

v2.4.0.8
Condensed Statement Of Operations (USD $)
3 Months Ended 9 Months Ended
Sep. 30, 2014
Sep. 30, 2013
Sep. 30, 2014
Sep. 30, 2013
Revenues:        
Research            
Expenses:        
General and administrative 1,211,842 932,762 4,327,787 3,001,460
Research and development 1,824,740 781,281 4,797,721 2,258,877
Patent fees 101,380 100,199 268,810 357,906
Depreciation and amortization 3,744 9,645 22,418 28,196
Total Expenses 3,141,706 1,823,887 9,416,736 5,646,439
Loss from Operations (3,141,706) (1,823,887) (9,416,736) (5,646,439)
Other Income (Expense)        
Interest income 34,864 13,293 105,190 34,744
Unrealized gain/(loss) on fair value of warrants 1,201,394 (217,751) (6,793,765) (1,055,505)
Financing expense   (112,559) (206,172) (112,559)
Total Other Income (Expense) 1,236,258 (317,017) (6,894,747) (1,133,320)
Net Loss Before Provision for Income Taxes (1,905,448) (2,140,904) (16,311,483) (6,779,759)
Provision for income taxes            
Net Loss $ (1,905,448) $ (2,140,904) $ (16,311,483) $ (6,779,759)
Net loss per share, basic and diluted $ (0.01) $ (0.02) $ (0.09) $ (0.06)
Weighted average number of shares outstanding, basic and diluted 178,219,622 130,466,114 175,383,673 123,188,044